嵌合抗原受体 T 细胞在异基因造血干细胞移植中的应用。
Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
机构信息
Department of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, People's Republic of China.
Division of Periodontology, Diagnostic Sciences & Dental Hygiene, & Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
出版信息
Immunotherapy. 2019 Jan;11(1):37-44. doi: 10.2217/imt-2018-0089.
The chimeric antigen receptor T (CAR-T) cells play an antileukemia role, and can be used to treat or prevent relapse by targeting minimal residual disease for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the infusion of allogeneic CAR-T cells may also cause graft-versus-host disease, which limited their applications during and after allo-HSCT. In this review, we discuss the clinical trials that applying CAR-T cells before allo-HSCT and the use of donor-derived CAR-T cells as conditioning regimen during allo-HSCT. At last, we analyzed the effect of donor-derived CAR-T cells on preventive infusion after allo-HSCT.
嵌合抗原受体 T（CAR-T）细胞具有抗白血病作用，可通过针对接受异基因造血干细胞移植（allo-HSCT）患者的微小残留病来治疗或预防复发。然而，输注异基因 CAR-T 细胞也可能导致移植物抗宿主病，这限制了它们在 allo-HSCT 期间和之后的应用。在这篇综述中，我们讨论了在 allo-HSCT 之前应用 CAR-T 细胞的临床试验，以及在 allo-HSCT 期间使用供体来源的 CAR-T 细胞作为预处理方案。最后，我们分析了供体来源的 CAR-T 细胞对 allo-HSCT 后预防性输注的影响。
Zotero 插件